Humacyte (HUMA) Shares Outstanding (2020 - 2026)

Humacyte (HUMA) has reported Shares Outstanding (Entity) for 7 consecutive years, with $277.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 77.69% year-over-year to $277.8 million in Q2 2026; TTM through Jun 2026 was $277.8 million, a 77.69% increase from a year earlier, with the FY2025 full-year figure at $158.2 million, up 21.64% from the prior year.
• Shares Outstanding (Entity) was $277.8 million for Q2 2026 at Humacyte, up from $222.0 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $277.8 million in Q2 2026 and troughed at $103.0 million in Q1 2022.
• A 5-year average of $135.7 million and a median of $119.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) surged 1966.4% in 2022 and climbed 0.32% in 2023, its largest moves.
• Over 5 years, Shares Outstanding (Entity) stood at $103.2 million in 2022, then increased by 0.43% to $103.7 million in 2023, then rose by 25.42% to $130.0 million in 2024, then climbed by 21.64% to $158.2 million in 2025, then soared by 75.64% to $277.8 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $277.8 million (Q2 2026), $222.0 million (Q1 2026), and $158.2 million (Q4 2025), per Business Quant data.